Temozolomide Chronotherapy for High Grade Glioma

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 11, 2016

Primary Completion Date

July 18, 2024

Study Completion Date

July 18, 2024

Conditions
GliomaGlioblastoma Multiforme
Interventions
DRUG

Temozolomide

-Given standard of care

OTHER

Functional Assessment of Cancer Therapy - Brain

"* 23-item questionnaire that can be completed in 5 to 10 minutes with little or no assistance in patients who are not neurologically incapacitated. This brain subscale is usually used along with the core (general) questionnaire \[2\] that includes 27 items.~* Patients rate all 5 items using a five-point Likert scale ranging from 0 not at all to 4 very much. Overall, higher ratings suggest higher QOL. Items are totaled to produce the following subscales, along with an overall QOL score: physical well-being (7 items); social/family well-being (7 items); emotional well-being (6 items); functional well-being (7 items); and concerns relevant to patients with brain tumors (23 items)~* The sleep portion of this questionnaire consists of 17 questions about sleeping patterns and the ability to rate severity of insomnia."

OTHER

ActTrust Condor Instrument Watch

-Will be required to wear 24 hours per day and will only be removed at specified data collection time points

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT02781792 - Temozolomide Chronotherapy for High Grade Glioma | Biotech Hunter | Biotech Hunter